Physician profile
Ryan Huu-Tuan Nguyen
NPI 1437509072
$215,725.57
in general payments reported to CMS, 2019-2025
28 companies · $114K in 2025
The $114K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,121 · 2022: $1,103 · 2023: $22K · 2024: $78K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $143K · Consulting Fee: $32K · Travel and Lodging: $29K · Food and Beverage: $6,608 · Honoraria: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $142,941.86 |
| Consulting Fee | $32,482.75 |
| Travel and Lodging | $29,468.16 |
| Food and Beverage | $6,608.49 |
| Honoraria | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $80,317.39 | 2022-2025 | Keytruda |
| Pfizer INC. | $64,179.90 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $45,236.71 | 2022-2025 | Opdivo |
| Emd Serono, INC. | $6,469.94 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $4,898.20 | 2023-2025 | Libtayo |
| Regeneron Healthcare Solutions, INC. | $3,272.92 | 2022-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $2,415.00 | 2025 | Alunbrig |
| Immunocore Limited | $2,211.04 | 2024-2025 | Kimmtrak |
| Genentech, INC. | $2,017.50 | 2025 | |
| Array Biopharma INC | $1,490.73 | 2024 | Mektovi, Braftovi |
| Promega Corporation | $1,000.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $813.87 | 2024-2025 | Imfinzi |
| Exelixis INC. | $453.91 | 2024-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $173.35 | 2025 | |
| Seagen INC. | $143.24 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $124.95 | 2022 | |
| Janssen Scientific Affairs, LLC | $98.59 | 2023 | Akeega, Rybrevant, Balversa |
| Abbott Laboratories | $86.48 | 2023-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Bayer Healthcare Pharmaceuticals INC. | $85.28 | 2024 | |
| Genentech USA, INC. | $72.94 | 2023-2024 | Phesgo, Kadcyla, Perjeta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.68 | 2023 | |
| Lilly USA, LLC | $50.42 | 2022-2024 | Verzenio, Jaypirca |
| Tempus Ai, INC | $26.83 | 2025 | Xt Cdx |
| Biotissue Holdings INC. | $22.70 | 2024 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.